Tenax Therapeutics has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $9 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Tenax Therapeutics is raising $9,000,000.00 in new funding. About Tenax Therapeutics: Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
To learn more about Tenax Therapeutics, visit http://tenaxthera.com/
Contact:
Christopher Giordano, Chief Executive Officer
919-855-2100
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.